

Antiobesity Pharmacotherapy: New Drugs and Emerging Targets

GW Kim¹, JE Lin¹, ES Blomain¹ and SA Waldman¹

Obesity is a growing pandemic, and related health and economic costs are staggering. Pharmacotherapy, partnered with lifestyle modifications, forms the core of current strategies to reduce the burden of this disease and its sequelae. However, therapies targeting weight loss have a significant history of safety risks, including cardiovascular and psychiatric events. Here, evolving strategies for developing antiobesity therapies, including targets, mechanisms, and developmental status, are highlighted. Progress in this field is underscored by Belviiq (lorcaserin) and Qsymia (phentermine/topiramate), the first agents in more than 10 years to achieve regulatory approval for chronic weight management in obese patients. On the horizon, novel insights into metabolism and energy homeostasis reveal guanosine 3',5'-cyclic monophosphate (cGMP) signaling circuits as emerging targets for antiobesity pharmacotherapy. These innovations in molecular discovery may elegantly align with practical off-the-shelf approaches, leveraging existing approved drugs that modulate cGMP levels for the management of obesity.

Obesity is a global public health problem. The obesity epidemic has been growing in developed nations, including the United States, for decades.¹ Moreover, this epidemic has spread to developing nations.¹ Growing affluence has been accompanied by the emergence of overweight and obesity, so much so that the proportions of underweight and overweight have become inverted.¹ The worldwide burden is estimated at 1.5 billion overweight and 500 million obese individuals.² The negative consequences of obesity have been quantified as exceeding those of either alcohol abuse or smoking.² Obesity-associated comorbidities, including major diseases such as cardiovascular disease, cancer, and diabetes, are legion.³ Overweight and obesity constitute the fifth leading risk for global deaths.² In June 2013, the American Medical Association officially recognized obesity as a disease.⁴

The evidence has been readily available and mounting, demonstrating the profound impact of obesity on morbidity, mortality, health-care costs, and professional and personal quality of life.² The awareness of this crisis has done little to reverse the obesity trends among the global population. Neither has the awareness that healthier habits for eating and exercise can be curative proved particularly effective. To blame are a host of factors: the lack of access to healthy, affordable foods or safe places for physical activity, particularly in lower-income neighborhoods and communities; the inferiority of freshly

prepared foods vs. fast foods or prepackaged foods in terms of preservation, portability, and palatability; the marketing of mostly unhealthy products by the food and beverage industry; and modern cultural habits that increase sedentary behaviors, degrade eating cadences and locations, and incur excess stress levels and sleep debt.^{1,2}

Amid the waves of reports publicizing these threats, there are glimmers of hope. Among the most troubling obesity-related trends has been the threefold increase in childhood obesity rates in the past 30 years.⁵ Consequently, children are increasingly being diagnosed with traditionally adult-onset diseases such as heart disease and type 2 diabetes.⁵ Furthermore, the likelihood and severity of obesity in adulthood is dramatically heightened by obesity in childhood.⁵ This problem has been met with an extensive fight to limit and reverse this disease. Public programs have developed health promotional campaigns focused on (i) raising a new generation of children with healthier habits regarding diet and physical activity and (ii) changing the complexion of school foods and beverages from high-calorie/high-fat/high-sodium junk foods and sugar-rich sodas to more fresh fruits and vegetables, whole grains, and healthier beverages. Public policy measures, such as container size limits and sugar taxes, are curbing the consumption of sugary high-calorie drinks.⁶ Recent data suggest that these efforts are succeeding modestly in trimming the growth of the overweight population;

¹Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Correspondence: SA Waldman (scott.waldman@jefferson.edu)

Received 3 September 2013; accepted 18 September 2013; advance online publication 13 November 2013. doi:10.1038/clpt.2013.204

however, the overall rates of overweight adults and children remain stubbornly large.⁷

Bariatric surgery reduces the size of the stomach, increases the feeling of fullness, and reduces the amount of food intake.⁸ Different types of bariatric surgery include the following: Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch, vertical sleeve gastrectomy, and adjustable gastric banding. Bariatric surgery has demonstrated efficacy in inducing sustained weight loss and improvements in blood pressure, glycemic control, and lipid profiles. Improvements and innovations in surgical techniques have reduced invasiveness, surgical risk, and recovery times. Furthermore, evolving guidelines have lowered the body mass index thresholds and expanded the patient population eligible for this treatment option, which has traditionally been indicated for only the extremely obese. Notably, bariatric surgery has been increasingly prominent in diabetes management, with a dramatic effect on glycemic control independent of weight loss.⁹ Nonetheless, bariatric surgery still has serious risks of surgical and metabolic complications, and it remains very expensive, making it less than ideal for the majority of the obese population.

Given the failure of lifestyle modifications to effect meaningful change and the limitations of bariatric surgery, the use of antiobesity drugs as adjuncts in obesity therapy is vital. The goal is not to hunt for a magic pill, as the long history of weight-loss drugs has seen the rise and fall of countless agents that proved highly effective but ultimately dangerous (**Table 1**). The goal is to use a safe and effective drug regimen, in combination with improved diet and exercise, to achieve a meaningful and sustainable reduction in body weight and enjoy the consequent benefits.

For regulatory agencies such as the US Food and Drug Administration (FDA), caution is key. Efficacy must go hand in hand with safety. The FDA's efficacy benchmarks require (i) that the difference in mean weight loss between the drug and the placebo groups is at least 5% for at least 1 year and statistically significant, and (ii) that the proportion of subjects who lose at least 5% of baseline body weight in the active product group is at least 35% and is approximately double the proportion in the placebo-treated group.⁵ Moreover, the obese population is heterogeneous, with variations in degree and duration of overweight, age, and associated comorbidities. A weight-loss drug must be compatible with the profile of an individual obese patient to be truly meaningful in terms of efficacy, safety, and durability. These necessary but demanding requirements have resulted in very limited pharmacotherapeutic options. As of September 2013, only three drugs are approved by the FDA as adjunctive therapy for chronic weight management: orlistat (Alli, GlaxoSmithKline; Xenical, Roche), approved in 1999; lorcaserin (Belviq, Arena Pharmaceuticals), approved in 2012; and phentermine/topiramate extended-release formulation (Qsymia, Vivus), also approved in 2012. Nonetheless, drug development programs have been investigating the molecular mechanisms underlying the regulation of appetite and metabolism (**Figure 1**) and translation of their discoveries into new pharmacotherapeutic agents and molecular targets to address the dual mandate of safety and efficacy.

SAFETY ISSUES WITH WEIGHT-LOSS DRUGS

Drugs can be very effective in inducing weight loss. The history of dietary supplements is full of success stories in terms of efficacy, but this success is matched by tragedy with regard to safety. Perhaps the most infamous is the combination drug Fen-Phen. A combination of the amphetamine analogs fenfluramine and phentermine, Fen-Phen's effectiveness helped it to achieve extensive popularity in the 1990s. Unfortunately, it also caused pulmonary hypertension and valvular heart disease, which forced its withdrawal from the market and birthed a legal and financial disaster.¹⁰ Other amphetamine analogs and sympathomimetics have had similarly grave risks, including addiction, myocardial toxicity, and sudden death.¹¹ Aminorex caused chronic pulmonary hypertension with 50% mortality.⁵ Phenylpropanolamine caused intracranial bleeding and strokes.¹² Ephedrine caused heart attacks, hypertension, palpitations, strokes, and sudden death.¹³ Sibutramine caused increased cardiovascular events.¹⁴ Rimonabant, an inverse agonist of the endocannabinoid receptor CB1, caused increased depression and suicide.¹⁵ These unsafe drugs have had their regulatory approval withdrawn, although their unregulated use may continue to some extent.

As of September 2013, only one drug, orlistat, has been approved by both the FDA and the European Medicines Agency (EMA) for chronic weight management. Orlistat is also the only FDA-approved weight-loss drug that is available without a prescription. It was approved in 1999 for prescription sale and in 2007 for over-the-counter sale. Orlistat inhibits gastrointestinal lipases, reducing fat absorption (**Figure 2c**). Consequently, its most common adverse effect is steatorrhea. Despite its approved status, orlistat has had a number of safety issues, including hepatotoxicity, nephrotoxicity, pancreatitis, and kidney stones.⁵

In 2010, the FDA rejected two proposed weight-loss drugs, lorcaserin and phentermine/topiramate (extended-release formulation) due to safety and efficacy issues. Major concerns over lorcaserin included limited efficacy, carcinogenesis, cardiovascular events, cognitive impairment, and psychiatric disorders. Major concerns over phentermine/topiramate included cardiovascular events, fetal toxicity, and suicidal ideation. In 2012, the FDA reversed its position and granted approval to both lorcaserin and phentermine/topiramate. Nonetheless, the FDA has required postmarketing safety studies to address the original cardiovascular concerns. Furthermore, the EMA has rejected both lorcaserin and phentermine/topiramate. The EMA rejected lorcaserin due to its opinion that the drug's benefits did not outweigh its risks, particularly the potential risk for tumors,¹⁶ and phentermine/topiramate due to concerns over the potential cardiovascular and central nervous system effects associated with its long-term use, its teratogenic potential, and its use by patients for whom it is not indicated.¹⁷


Despite their limitations, lorcaserin and phentermine/topiramate represent the first new antiobesity drug approvals in 13 years (**Figure 2a,b**). In this article, we discuss these two new drugs in more detail. We also discuss other promising weight-loss agents that are currently in development and undergoing

Table 1 Current antiobesity medications

| Mechanism of action | Drug | Effects and safety concerns | Efficacy | Status |
|---|---------------------------------|---|--|--|
| Appetite suppressant. Stimulates anorexic signaling in hypothalamus or dopamine receptor in the hippocampus. Sympathomimetic agent similar to norepinephrine with central nervous system stimulatory activity | Phentermine | Appetite suppression and weight loss Side effects include dizziness, dry mouth, difficulty in sleeping, irritability, nausea, vomiting, diarrhea, or constipation. This drug has withdrawal symptoms | Weight loss greater than placebo was 3.6 kg (CI: 0.6–6.0 kg) | Approved by the FDA in 1959 |
| | Amphetamine | Anorexia and weight loss Side effects include nervousness, restlessness, excitability, dizziness, headache, fear, anxiety, and tremor. Blood pressure and heart rate may increase. Chronic use may lead to dependence. These drugs have withdrawal symptoms | Weight loss greater than placebo was <1 kg (CI: 0.5–1.6 kg) | Off-label usage; approved for attention-deficit hyperactivity disorder |
| Serotonin, dopamine, and norepinephrine reuptake inhibitor that potentiates the neurotransmitter activity in the central nervous system | Lorcaserin (Belviq) | Limited weight-loss efficacy and possible increase in cancer risk Side effects include headache, infection, sinusitis, nausea, depression, anxiety, and suicidal thoughts. Possible concerns of cancer risk | Mean body weight loss: lorcaserin 5.8 ± 0.2 kg; placebo 2.2 ± 0.1 kg | Approved by the FDA in 2012 |
| | Desvenlafaxine (Pristiq) | Anorexia, but effect on body weight is unclear Vision problems, headache, low libido, dry mouth, dizziness, insomnia, taste problems, vomiting, anxiety, sexual dysfunction, depression, high blood pressure, stomach ache, numbness and tingling, fatigue, and involuntary quivering | Mean body weight loss greater than placebo was 0.22–1.41 kg | Off-label usage; approved for depression |
| | Sibutramine (Meridia) | Limited weight-loss efficacy Increased risk for cardiovascular events and stroke | | Approved by the FDA approval in 1997 but withdrawn in 2010 due to cardiovascular effects |
| Inhibits the neuronal uptake of dopamine, norepinephrine, and serotonin | Bupropion (Wellbutrin, Zyban) | Modest weight loss Nausea, vomiting, dry mouth, headache, constipation, increased sweating, joint aches, sore throat, blurred vision, strange taste in the mouth, agitation and insomnia, tremor, or dizziness may occur. Rare side effects include cardiovascular effects, hearing problems, severe headache, an increase in suicide risk, and respiratory problems | % Weight loss greater than placebo: bupropion SR 400 mg/day 5.1% (CI: 6.9–3.2%); bupropion SR 300 mg/day 2.2% (CI: 4.0–0.4%) | Off-label usage; approved for depression |
| Reversible inhibitor of intestinal lipases | Orlistat (Xenical) | Weight loss Increased number of bowel movements and potential changes in the bowel function and microbiota | Mean body weight loss greater than placebo was 4.2 kg | Approved by the FDA in 1999 |
| Enhancing GABA signaling to promote anorexigenic signaling. Inhibiting voltage-gated channels and AMPA receptor in the orexigenic neurons | Topiramate (Topamax) | Appetite suppression and weight loss Fatigue, drowsiness, dizziness, loss of coordination, tingling of the hands/feet, bad taste in the mouth, and diarrhea. Mental problems such as confusion, slowed thinking, trouble concentrating or paying attention, nervousness, memory problems, or speech/language problems may also occur. Rare side effects include kidney stones, depression, suicidal thoughts/attempts, and vision loss | Weight loss greater than placebo was 6.5 kg (CI: 4.8–8.3 kg) | Off-label usage; approved for epilepsy |
| GLP-1 receptor agonist | Exenatide (Byetta, Bydureon) | Decreased blood glucose level and body weight Side effects include gastrointestinal symptoms, acute pancreatitis, dizziness, and headache. It might increase risks of sulfonylurea-induced hypoglycemia and thyroid cancer | Mean body weight change: exenatide –(2.49 ± 0.66) kg, placebo +(0.43 ± 0.63) kg | Off-label usage; approved for diabetes |
| | Liraglutide (Victoza) | Maintained normal blood glucose and body weight Increased risks of C-cell carcinoma and thyroid C-cell focal hyperplasia were observed in rats and mice | Weight loss greater than placebo was 4.4 kg (CI: 2.9–6.0 kg) | Off-label usage; approved for diabetes |
| Amylin analog | Pramlintide (Symlin) | Decreased blood glucose level and body weight Side effects include nausea, hypoglycemia, vomiting, headache, abdominal pain, and fatigue | % Weight loss greater than placebo was 2.2 ± 0.7% | Off-label usage; approved for diabetes |
| Cocktail drug | Phentermine/topiramate (Osymia) | See above effects from individual drugs | % Weight loss from baseline was placebo –2.2%, (PHEN 7.5 mg/TPM 46 mg) CR –9.3%, and (PHEN 15 mg/TPM 92 mg) CR –10.7% | Approved by the FDA in 2012 |

The various shades (low, medium, and high) represent FDA approval status and off-label usage of drugs.

AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionate; CI, confidence interval; CR, controlled release; FDA, US Food and Drug Administration; GABA, γ-aminobutyric acid; GLP-1, glucagon-like peptide 1; PHEN, phentermine; SR, sustained release; TPM, topiramate.



Illustrated by Zina Deretsky

Figure 1 Central regulation of appetite and energy homeostasis. The hypothalamus is the major site of integration of anorexigenic and orexigenic signaling. Peripheral satiety hormones, such as ghrelin from the stomach and leptin from adipose tissue, primarily bind and activate their cognate receptors directly in the hypothalamus, particularly in the arcuate nucleus, or in the dorsal vagal complex in the medulla, which communicates with the hypothalamus. Among the neurons in the arcuate nucleus, there exist two populations of neurons: those expressing the orexigenic neuropeptide Y (NPY) or agouti-related peptide (AgRP), and those expressing the anorexigenic pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Several satiety hormones induce their anorectic effects by either inhibiting the activity of NPY/AgRP neurons or activating POMC/CART neurons. These neurons in the arcuate nucleus project to second-order neurons in other hypothalamic nuclei, including the paraventricular nucleus (PVN), dorsomedial nucleus (DMN), ventromedial nucleus (VMN), and lateral hypothalamic area (LHA). These second-order hypothalamic neurons express anorexigenic neuropeptides (corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and brain-derived neurotrophic factor (BDNF)) and orexigenic neuropeptides (orexin (ORX) and melanin-concentrating hormone (MCH)), which modulate appetite and energy homeostasis. Furthermore, the regulation of energy balance involves an integration of signaling from the hypothalamus, brain stem, and reward pathways of the mesolimbic system. Symbols: blue receptor, activating; red receptor, inhibiting; blue arrow, appetite-stimulating pathway; red arrow, appetite-suppressing pathway. GLP-1R, glucagon-like peptide 1 receptor.

clinical trials, as well as future directions in medical weight-loss strategies.

ORLISTAT (ALLI, XENICAL)

Orlistat is a gastrointestinal lipase inhibitor. It was approved by the FDA for prescription sale in 1999 and for over-the-counter sale in 2007. Because of the safety-related withdrawals of other drugs from the market, orlistat was the sole drug approved by the FDA for adjunctive use in long-term weight management until the 2012 approvals of lorcaserin and phentermine/topiramate. Moreover, orlistat remains the only antiobesity drug approved by the EMA. Orlistat acts by binding and inhibiting lipases that are produced by the pancreas and stomach and that act in the small intestine to break down dietary triglycerides into free fatty acids, which can be absorbed via fatty acid transporters expressed by the intestinal epithelial cells (Figure 2c). Thus, by inhibiting these lipases, orlistat reduces systemic fat absorption. Unsurprisingly, a major adverse effect is steatorrhea. In obese patients started on a controlled-energy diet, orlistat (120 mg t.i.d.) induced more weight loss (3%) after 1 year, produced less weight regain after 2 years, and was associated with improvements in fasting low-density lipoprotein cholesterol and insulin levels vs. placebo.¹⁸ Although orlistat has remained approved

and has modest but demonstrated efficacy, it has garnered attention by the FDA and Public Citizen, a nonprofit consumer rights advocacy group, because of safety issues. Risks include severe liver damage, acute pancreatitis, acute renal failure, and precancerous colon lesions.¹⁹ In summary, the modest efficacy, undesirable adverse effects, and serious health risks combine to highlight the deficiencies of orlistat and underscore the pressing need for other antiobesity drug options.

LORCASERIN (BELVIQ)

Serotonin, or 5-hydroxytryptamine (5-HT), is an important neurotransmitter that regulates food intake behaviors in both invertebrates and vertebrates (Figure 2).^{20,21} In more complex animals, including humans, serotonin mediates multiple processes in the central nervous system through 14 distinct 5-HT receptors belonging to seven families.²¹ The serotonergic neurons project axons into almost all brain areas and the spinal cord to release 5-HT to activate serotonin-sensitive neurons in virtually all regions of the central nervous system, mainly from the raphe nuclei of the midbrain.²¹ It is notable that the majority of the serotonin-sensitive neurons are heteroreceptors, which release different neurotransmitters from those that activate them.²¹ One of the physiological processes that serotonin




Figure 2 Molecular targets for antiobesity pharmacotherapeutics. **(a)** Phentermine stimulates the release of dopamine (DA) into the synapse from the presynaptic dopaminergic neurons from the ventral tegmental area (VTA). This released dopamine binds and activates dopamine receptors, including D1 and D2, on postsynaptic neurons in the nucleus accumbens. Dopamine is taken back up into the presynaptic neuron by the dopamine transporter (DAT), which is bound and inhibited by bupropion. Pramlintide and davalintide are amylin analogs that activate amylin receptors (CTR) in the dorsal vagal complex (DVC). Exenatide, liraglutide, and NN9924 are GLP-1 analogs that activate GLP-1 receptors (GLP-1R) in the hypothalamus and DVC. S-2367 binds and inhibits Y5 receptors in the hypothalamic paraventricular nucleus (PVN) to suppress neuropeptide Y (NPY) signaling. RM-493 is a melanocortin 4 receptor (MC4R) agonist that binds and activates MC4R in the PVN and lateral hypothalamic area (LHA). Topiramate induces γ -aminobutyric acid (GABA) receptor-mediated inhibitory currents. TKS1225 and OXY-RPEG are oxyntomodulin (OXM) analogs that bind and activate GLP-1R in the arcuate nucleus and DVC. Lorcaserin selectively binds and activates 5-HT_{2c} serotonin receptors in the arcuate nucleus. Symbols: blue receptor, activating; red receptor, inhibiting. **(b)** Topiramate's exact mechanism of action is unknown but may involve its ability to block voltage-gated sodium channels in the presynaptic excitatory neuron, antagonize α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/N-methyl-D-aspartate (AMPA/NMDA) glutamate receptors on postsynaptic neurons, and enhance the activity of inhibitory γ -aminobutyric acid (GABA) neurons. **(c)** Orlistat binds and inhibits gastric and pancreatic lipases in the intestine. These lipases hydrolyze dietary triglycerides into free fatty acids that can be absorbed by intestinal epithelial cells via fatty acid transporters. Thus, orlistat suppresses systemic lipid absorption.

regulates is postprandial satiety through hypothalamic serotonin 5-HT_{2C} receptors and, possibly, 5-HT_{1A}, 5-HT_{1B}, and 5-HT₆ receptors.²²

These receptors receive serotonin secreted from serotonergic neurons that project from the brain stem into the hypothalamus to orchestrate feeding behavior through the melanocortin (MC) system.²² Specifically, serotonin regulates appetite and body weight through MC4R in the arcuate nucleus (ARC; **Figure 1**). Activation of 5-HT_{2C} and 5-HT_{1B} receptors by serotonin increases the anorexigenic α -melanocyte-stimulating hormone and decreases the orexigenic agouti-related peptide (AgRP) in the presynaptic area of the ARC and promotes satiety through MC4R-expressing neurons.^{23,24} Silencing *Mc4r* in mice eliminates the appetite-suppressing effects mediated by 5-HT_{2C} and 5-HT_{1B} agonists, whereas expression of *Mc4r* in the ARC restores the ability of 5-HT compounds to regulate appetite.^{24,25}

Genetic manipulation of 5-HT receptors revealed that ablation of 5-HT receptors resulted in hyperphagia and obesity.²² Elimination of the G_i-coupled 5-HT_{1B} receptor (*Htr1b*) in mice exhibited only a limited increase in food consumption and body weight.^{25,26} However, genetic inactivation of the G_q-coupled receptor 5-HT_{2C}R (*Htr2c*) leads to hyperphagia and obesity, accompanied by partial leptin and insulin resistance.²⁷ Reinstating 5-HT_{2C}R on pro-opiomelanocortin (POMC) neurons in *Htr2c*^{-/-} mice is sufficient to mediate the serotonin effects on appetite and correct the hyperphagic and obese phenotypes.²⁷ In addition, pharmacologic or genetic inactivation of the 5-HT₃ receptor in the nucleus tractus solitarius of the dorsal vagal complex (**Figure 1**) promotes food intake in *Agrp*^{DTR} mice, whose orexigenic AgRP neurons were ablated by diphtheria toxin.²⁸ Accordingly, central serotonergic neurons may be a potential target to modulate food intake and energy homeostasis.

Lorcaserin (previously known as APD-356), marketed as Belviq by Arena Pharmaceuticals, is a selective 5-HT_{2C} receptor agonist that specifically activates 5-HT_{2C} receptors relative to other 5-HT receptor subtypes. This characteristic of lorcaserin limits the risk of hallucinations due to 5-HT_{2A} activation and the risk of cardiovascular side effects, including valvulopathy and pulmonary hypertension, through 5-HT_{2B} receptors.²⁵ This preferential affinity to 5-HT_{2C} receptors provides lorcaserin the efficacy of previous serotonergic antiobesity treatments without the undesirable safety concerns that led to their withdrawal.^{29,30} Lorcaserin has a half-life of about 11 hours and a median time to maximum concentration of 1.5–2 h.²⁵ Lorcaserin is metabolized by multiple hepatic pathways to inactive metabolites, which are thereafter excreted in the urine. This drug inhibits cytochrome P450 2D6 metabolism and cannot be cleared by hemodialysis.²⁵

Preclinical studies demonstrated that chronic administration of lorcaserin at doses of 4.5, 9, and 18 mg/kg reduced food consumption and prevented diet-induced obesity in mice.²⁵ In a multicenter, randomized, 52-week, placebo-controlled, double-blind trial, lorcaserin at a dose of 10 mg b.i.d. mediated an average weight loss of 5.8 ± 0.2 kg (5.8%) in 883 patients within 1 year, whereas the placebo induced an average weight loss of 2.2 ± 0.1 kg (2.2%) in 716 patients. There was no significant difference in adverse events between the lorcaserin and the placebo groups.³¹ The effect of

lorcaserin on body weight management was also examined in an 8-week, double-blind, placebo-controlled trial. Lorcaserin induced significant reduction of body weight and food intake in comparison with placebo and baseline.²⁵ In a number of phase III trials, including the BLOOM-DM (Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) and BLOSSOM (Behavioral Modification and Lorcaserin Second Study for Obesity Management) studies, subjects in the lorcaserin groups achieved significantly greater weight loss than those in the placebo groups.^{32,33}

Lorcaserin has safety concerns regarding psychiatric and cardiovascular risks that are similar to those of other 5-HT receptor agonists but to a lesser extent. The most common adverse events in nondiabetic patients include headache, dizziness, fatigue, nausea, dry mouth, and constipation. In diabetic patients, hypoglycemia, headache, back pain, cough, and fatigue are the major complaints.^{31–33} Potential life-threatening serotonin syndrome or neuroleptic malignant syndrome-like reactions might take place if lorcaserin is used in combination with drugs that impair metabolism of serotonin or increase presynaptic serotonin concentration.²⁵ In very rare cases, lorcaserin induces changes in the heart, as evidenced by echocardiography, and possibly causes valvular heart diseases. Other potential side effects include cognitive impairment, psychiatric disorders, priapism, bradycardia, hematological changes, prolactin elevation, and pulmonary hypertension.²⁵ The effect of lorcaserin on breast cancer risk is unclear. Given that lorcaserin increases breast cancer risk in rats, long-term postmarketing safety monitoring is required to evaluate the potential risks and safety concerns, in addition to unexpected adverse events.

PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE FORMULATION (QSYMIA)

Many etiologies contribute to obesity in humans. This disease is caused by the confluence of a variety of factors, including energy imbalance, disruption of neuroendocrine axes, and adverse psychological factors. Given this complex etiology, it is unlikely that monotherapy will be sufficient to reverse the disease. It is therefore not surprising that combination therapies have been evaluated clinically, and these show substantial promise in the treatment of obesity. One such cocktail therapy that has recently been approved for treatment of obesity is phentermine/topiramate extended-release formulation, which is being marketed in the United States as Qsymia by Vivus.

Phentermine has been used in the United States since 1959 for short-term management of obesity.²⁵ Its mechanism of action is believed to be dependent on modulation of catecholamines in the satiety centers of the hypothalamus, reducing appetite.²⁵ Topiramate has also been approved by the FDA, although it is primarily used to treat convulsive disorders and migraines. Interestingly, it was observed that patients receiving topiramate lost weight, and this generated interest in evaluating this compound as a potential antiobesity drug.^{34–36} Topiramate enacts its effects at least partially through antagonism of α -amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptors, although induction of γ -aminobutyric acid (GABA)

receptor-mediated inhibitory currents and modification of voltage-gated calcium and sodium channels may also play a role (Figure 2b).³⁷ Animal studies suggest that topiramate induces weight loss not only by decreasing food intake but also by increasing energy expenditure, possibly through decreased efficiency of nutrient utilization.^{38–40} Although the exact mechanisms by which topiramate regulates appetite and induces weight loss in humans is unknown, significant clinical evidence exists to support its use as an antiobesity drug.^{34–36}

The FDA approved the combination of phentermine/topiramate in 2012, largely on the strength of evidence from three clinical trials, known as the CONQUER, EQUIP, and SEQUEL trials.^{41–43} Data from these three trials showed phentermine/topiramate to be efficacious in inducing and maintaining weight loss. Across the three trials, ~75% of treated subjects exhibited a 5% weight loss, and ~50% exhibited a 10% weight loss. These benchmarks represent important efficacy thresholds in evaluation of obesity pharmacotherapies. Importantly, this weight loss was accompanied by improvement in weight-related comorbidities, including serum lipid profile, waist circumference, and blood pressure. It is unclear whether sustained weight loss requires indefinite treatment with phentermine/topiramate, but it has been speculated that discontinuation of the drug may lead to weight regain.²⁵

Although drug interactions are rare for phentermine/topiramate, adverse events observed in clinical trials include paresthesias, headaches, constipation, dry mouth, upper respiratory tract infection, nasopharyngitis, dizziness, insomnia, depression, anxiety, blurry vision, and irritability.^{41–43} Given this lengthy list of events, it is not surprising that one clinical trial of phentermine/topiramate reported a dropout rate of ~19% (although another trial reported this number to be as low as 4%).^{42,43} A more serious potential adverse event involves the risk of cardiovascular events. Although patients treated with phentermine/topiramate in clinical trials exhibited a slight increase in heart rate, the risk of cardiovascular events is unclear at this time and is being monitored by Vivus in postmarketing studies.^{41–44}

In addition to adverse events observed in clinical trials, several other safety issues cloud the use of phentermine/topiramate. Given the addictive potential of amphetamines, there was some concern regarding widespread use of phentermine. However, a study investigating the addictive potential of phentermine showed only minimal addictiveness, allaying these concerns.⁴⁵ Importantly, phentermine/topiramate is also a teratogen, classified as a pregnancy category X drug.²⁵ Amid these concerns, the FDA approved the combinatorial therapy with a Risk Evaluation and Mitigation Strategy (REMS).²⁵ As with the cardiovascular risks, Vivus is engaged in a rigorous postmarketing surveillance program to evaluate these teratogenic risks.^{25,44}

Weight regain remains a significant limitation among patients attempting to lose weight. Although interventions such as lifestyle modification, pharmacotherapy, or bariatric surgery are effective in inducing weight loss initially, most subjects will eventually regain their lost weight. Given the importance of weight maintenance in the long-term disease prognosis for obese patients, the mechanisms underlying weight regain

remain important and actively researched questions. In the context of the substantial problem of weight regain, persistence of the weight-loss response is desirable in any potential obesity therapy. Importantly, topiramate appears to possess this important characteristic. In several clinical trials, cohorts of patients treated with topiramate maintained weight loss as long as 1 year, even after the placebo group had exhibited marked weight regain.^{34,35} Importantly, one of the clinical trials evaluating the combination of phentermine/topiramate showed a sustained weight loss at 2 years of follow-up.⁴³

The persistent and robust clinical effects of phentermine/topiramate may be attributable to the complementary effects of these two compounds. The chronology of weight loss induced by both the two compounds may represent the source of this complementarity. Phentermine induces weight loss in the short term, whereas topiramate has been shown to be a longer-term agent. In addition to chronology, complementary effects may exist in the mechanisms by which the compounds induce weight loss. Interestingly, several studies have documented the ability of topiramate to reduce calorie intake.^{46,47} These studies have suggested that this effect may be due to topiramate's ability to inhibit compulsive food cravings and addictive behavior. This observation is based largely on the clinical efficacy of topiramate in treating binge eating disorder through antagonism of α -amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptors.^{46–48} These beneficial psychological effects may behave synergistically with neuroendocrine mechanisms of inducing weight loss. This makes phentermine/topiramate unique in obesity therapeutics in that it targets not only the neuroendocrine milieu of obesity but also the psychological factors of binge eating underlying the disease. These various complementary effects make this regimen unique among its peers and may represent an important paradigm in the future development of combinatorial therapies.

ANTIOBESITY DRUGS IN THE PIPELINE

A fundamental trait shared by many antiobesity drugs under development is the targeting of endogenous endocrine circuits regulating energy homeostasis. Most of these endocrine circuits are anorexigenic. Peripheral peptide hormones are released postprandially and travel in the circulation to their cognate receptors, which are expressed in the homeostatic regulatory centers in the central nervous system, notably the ARC of the hypothalamus and the dorsal vagal complex in the medulla. The ARC is home to neurons expressing the key (i) orexigenic (stimulating appetite) neurotransmitters agouti-related peptide (AgRP) and neuropeptide Y (NPY) and (ii) anorexigenic (appetite-suppressing) neurotransmitters POMC and the cocaine- and amphetamine-regulated transcript (Figure 2).

POMC itself is cleaved to yield several hormones, including α -melanocyte-stimulating hormone, which binds the melanocortin 3 and melanocortin 4 receptors (MC3R and MC4R, respectively) to transmit the anorexigenic signal. Rhythm has developed the MC4R agonist RM-493 (Table 2). In preclinical studies, obese primates treated for 8 weeks lost an average of 13.5% of their body weight, with significant improvements in both insulin sensitivity and cardiovascular function. However,

in a trial with obese human subjects, Merck's MC4R agonist MK-0493 induced only a small, statistically insignificant weight reduction as compared with placebo after 12 weeks in a fixed-dose study or after 18 weeks of stepped-titration dosing.⁴⁹ As Merck's MK-0493 was promising at the preclinical stage but only tested in rodents, that Rhythm's RM-493 preclinical success was in primates may be more predictive of the results in humans. Rhythm initiated phase II trials of RM-493 in December 2012, with completion scheduled for October 2013.⁵ Due to the role of MCs in cardiovascular and sexual function, the potential off-target adverse effects of MC signaling in obesity treatment warrant scrutiny.⁵⁰ For example, phase I/II trials with the α -melanocyte-stimulating hormone analog, Melanotan II, caused dose-dependent penile erections.⁵¹

NPY activates G protein-coupled receptors Y1 and Y5 to stimulate appetite.⁵² Shionogi's S-2367 (Velneperit; **Figure 2**) is a Y5 receptor inhibitor that has completed phase II trials in the United States and is in a phase III trial in Japan initiated in August 2013 and scheduled for completion in March 2014. In combination with a reduced-calorie diet, 800 mg/d S-2367

vs. placebo induced at least 5% weight loss, reduced waist circumference, and improved lipid panels in obese patients over the course of 1 year.⁵³ It should be noted that neuropeptide Y5 receptor antagonism with Merck's MK-0557 failed to induce clinically meaningful weight loss in overweight and obese adults in a 52-week weight-loss study, despite its success in preclinical and proof-of-concept/dose-ranging studies.⁵⁴ The investigators concluded that neuropeptide Y5 receptor antagonism was insufficient as monotherapy for antiobesity drug therapy but discussed its potential in combination therapy.

Modulation of monoamine neurotransmitters, such as dopamine, norepinephrine, and serotonin, can be highly effective in suppressing appetite, but adverse effects such as cardiovascular events and addiction are major concerns with their use in weight management.⁵⁵ Orexigen Therapeutics has developed the combination drug bupropion/naltrexone (Contrave), which combines bupropion, a dopamine and norepinephrine reuptake inhibitor, and naltrexone, an opioid receptor antagonist. Bupropion increases dopamine activity and POMC neuronal

Table 2 Antiobesity medications under development

| Target | Drug | Company | Mechanism of action | Status |
|--------------------------------------|---------------------------------|------------------------|---|-------------------------------------|
| Central neuropeptide signaling | | | | |
| Melanocortin receptor | MK-0493 | Merck | Selective MC4R agonist, increases MC3R/4R signaling | Phase II completed |
| | RM-493 | Rhythm | Selective MC4R agonist, increases MC3/4R signaling | Phase II |
| NPY | MK-0557 | Merck | Y5 receptor antagonist, NPY blocker | Phase II completed |
| | Velneperit (S-2367) | Shionogi USA | Y5 receptor antagonist, NPY blocker | Phase III |
| Monoamine neurotransmission | | | | |
| Dopamine/norepinephrine/serotonin | Contrave (bupropion/naltrexone) | Orexigen | Norepinephrine/dopamine reuptake inhibitor | Phase III completed; NDA submission |
| Intestinal peptide hormone signaling | | | | |
| GLP-1 | Liraglutide (Victoza) | Novo Nordisk | GLP-1R agonist, GLP-1 mimicking | Phase III completed; NDA submission |
| | Byetta (Exenatide) | Amylin | GLP-1R agonist, GLP-1 mimicking | Phase III |
| OXM | Oxyntomodulin (OXY-RPEG) | Prolor | GLP-1R agonist, OXM mimicking | Phase I recruiting |
| | TKS1225 | Thiakis/Wyeth/Pfizer | GLP-1R agonist, OXM mimicking | Phase I |
| Pancreatic hormone signaling | | | | |
| PP | PP1420 | Wellcome Trust | Pancreatic polypeptide analog | Phase I completed |
| Amylin | Davalintide (AC2307) | Amylin | Amylin mimicking | Phase II |
| Adipose tissue hormone signaling | | | | |
| Leptin | Metreleptin | Amylin/Takeda | Leptin receptor agonist | Phase III recruiting |
| Inhibition of lipase | | | | |
| Pancreatic lipase | Cetilistat (ATL-962) | Alizyme/Takeda/Norgine | Pancreatic lipase inhibitor, inhibits intestinal lipid absorption | Phase III completed |

GLP-1, glucagon-like peptide 1; MC3R/4R, melanocortin 3 and melanocortin 4 receptors; NDA, New Drug Application; NPY, neuropeptide Y; OXM, oxyntomodulin; PP, pancreatic polypeptide.

activation, thereby reducing appetite and increasing energy expenditure (**Figure 2**). Naltrexone blocks opioid receptors on the POMC neurons, preventing feedback inhibition and further increasing POMC activity. In a comparison of combined bupropion (400 mg/d, sustained-release formulation) and naltrexone (48 mg/d) therapy for obesity vs. monotherapy or placebo, weight loss was 1.2 kg (1.1%) for placebo, 1.6 kg (1.7%) for naltrexone monotherapy, 3.1 kg (3.1%) for bupropion monotherapy, and 6.9 kg (7.5%) for naltrexone/bupropion combination therapy, which demonstrated their synergy.⁵⁶ In addition, bupropion/naltrexone may regulate activity in the dopamine reward system of the brain that helps control food cravings and overeating behaviors (**Figure 2**).⁵⁶ In phase III clinical trials, bupropion/naltrexone vs. placebo induced greater weight loss on a diet and exercise program over 56 weeks.⁵ In 2011, the FDA rejected bupropion/naltrexone and requested a large cardiovascular risk trial to address long-term adverse effects before it could approve the drug.⁵ Orexigen has begun the requested long-term clinical trial, and its New Drug Application has been submitted and reviewed by the FDA, with potential approval in late 2013 or early 2014.

Amylin, also called islet amyloid polypeptide, is synthesized by pancreatic β -cells and is secreted with insulin postprandially.⁵⁷ Amylin acts synergistically with insulin to regulate plasma glucose levels. Amylin's fasting plasma concentration is low and rises following food intake.⁵⁸ Amylin also functions as an anorectic, mediating appetite suppression via activation of amylin receptors in the area postrema of the dorsal vagal complex⁵⁷ and vagal signaling.^{59,60} The amylin analog pramlintide (Symlin), from Amylin Pharmaceuticals/Bristol-Myers Squibb/AstraZeneca, is already approved for diabetic adjunctive treatment.⁵ Notably, 120 μ g b.i.d. or 150 μ g q.d. pramlintide also induced an average weight loss of 2.6 kg over 1 year in type 2 diabetics, with minimal adverse effects.⁶¹ Amylin Pharmaceuticals' second-generation amylin analog, davalintide (AC2307), is in phase II trials for an obesity indication.

Leptin is a hormone made by adipose tissue and secreted into the circulation in proportion to its mass. Leptin activates leptin receptors, which are expressed throughout the body, with high expression in the hypothalamic ARC. Hypothalamic leptin receptor activation drives increased POMC expression and signaling and inhibits NPY/AgRP expression and signaling, thereby suppressing appetite.⁵ Conversely, a decreased fat mass results in lower plasma leptin concentrations, leading to increased appetite. Thus, leptin is a key hormone in the regulation of energy homeostasis. Patients with congenital leptin deficiency develop early-onset obesity and are responsive to leptin replacement therapy.^{62,63} Unfortunately, patients with diet-induced obesity develop leptin receptor resistance.⁶⁴ These patients have high plasma leptin concentrations, reflecting their high adiposity, but this high leptin level is ineffective in driving appetite reduction. Although leptin monotherapy appears intractable as a therapeutic option, the resensitization of the leptin receptor to its cognate hormone is an active strategy in antiobesity drug development. Intriguingly, the pancreatic hormone amylin restores leptin

receptor responsiveness to leptin in the setting of obesity.⁶⁵ Combination therapy comprising Amylin Pharmaceuticals' leptin analog, metreleptin, and its amylin analog, pramlintide, induced a greater and more durable weight reduction vs. monotherapy in phase II trials in overweight and obese patients.⁶⁶ Unfortunately, Amylin Pharmaceuticals and Takeda Pharmaceutical Company were forced to suspend the trials due to a laboratory finding involving antibody-mediated metreleptin neutralization.⁶⁷ Fortunately, other preclinical studies suggest that leptin resensitization is achievable with combination therapy comprising leptin analogs and other pharmacotherapeutic agents, namely, exendin-4 or fibroblast growth factor 21.⁶⁸

Glucagon-like peptide 1 (GLP-1) is derived from cleavage of the proglucagon gene product, which is synthesized by enteroendocrine L cells in the ileum and proximal colon.⁶⁹ GLP-1 is secreted following food intake and mediates a variety of functions: increased insulin secretion, decreased glucagon secretion, decreased gastric secretion and motility, increased satiety, and decreased food intake. Indeed, GLP-1 administration in preclinical and clinical trials induced satiety and weight loss.⁷⁰⁻⁷³ However, dipeptidyl peptidase-4 degrades endogenous GLP-1 in <2 minutes.⁷⁴ Consequently, degradation-resistant GLP-1 analogs have been developed to increase the practicality of GLP-1 pharmacotherapy. Liraglutide (Victoza) from Novo Nordisk is a GLP-1 analog that contains an amino acid substitution and a fatty acid attachment, which stabilize it against degradation by dipeptidyl peptidase-4. Its 13-hour half-life makes it suitable for once-daily administration. Exenatide (Byetta) from Amylin Pharmaceuticals/Bristol-Myers Squibb/AstraZeneca is an analog of exendin-4, a Gila monster salivary hormone with functions similar to those of GLP-1. As with the amylin analog pramlintide, liraglutide and exenatide are approved by the FDA for adjunctive therapy in type 2 diabetes.⁷⁵⁻⁷⁸ The potential of these drugs to treat both diabetes and obesity would be a major synergistic benefit considering the overlap in patient population and the close association between these diseases. Liraglutide and exenatide induced significant weight loss in diabetics. This weight loss was dose dependent, progressive, and durable over 30 weeks. In studies with nondiabetic obese patients, liraglutide drove a 6-kg (8%) weight loss, and >35% of the patients on the highest dose achieved weight loss of >10%. Novo Nordisk completed these phase III trials for liraglutide for an obesity indication in nondiabetic obese patients in September 2010 and in diabetic obese patients in January 2013. Novo Nordisk expects regulatory filings in the European Union and the United States to begin by the start of 2014. Bristol-Myers Squibb is scheduled to complete its phase III obesity trials on exenatide in February 2014. Furthermore, Novo Nordisk/Emisphere used Emisphere's proprietary oral sodium N-[8-(2-hydroxybenzoyl)amino] caprylate technology to develop the long-acting oral GLP-1 analog NN9924, which is in phase I trials in the United Kingdom.⁵

Like GLP-1, oxyntomodulin (OXM) is an anorexigenic peptide hormone produced from the processing of proglucagon and secreted postprandially with GLP-1 by the L cells in


the colon. Injections of OXM in humans caused a significant reduction in weight and appetite, in addition to an increase in energy expenditure. OXM is a dual agonist of the GLP-1R and the glucagon receptor, and it may exert its anorectic effects via activation of central GLP-1Rs and stimulation of POMC neurons in the ARC (Figure 2).^{5,79} Like GLP-1, rapid degradation makes endogenous OXM impractical for pharmacotherapy, but long-acting OXM analogs are in development. TKS1225 from Thiakis/Wyeth/Pfizer is in phase I trials. OXY-RPEG from PROLOR Biotech has been engineered with its proprietary reversible pegylation technology to increase its half-life, with an added benefit of increased potency. In preclinical testing, OXY-RPEG was significantly superior to twice-daily injections of OXM in the reduction of food intake and in the degree and durability of weight loss.⁵

THE EMERGING ROLE OF CYCLIC GUANOSINE MONOPHOSPHATE SIGNALING IN ANTI-OBESITY PHARMACOTHERAPY

Cyclic nucleotides, including 3',5'-cyclic guanosine monophosphate (cGMP) and 3',5'-cyclic adenosine monophosphate (cAMP), are second messengers important in many biological processes (Figure 3). The canonical role of cAMP in carbohydrate and lipid metabolism is well established, reflecting sophisticated studies of insulin and glucagon.⁸⁰ Specifically, binding of glucagon to an adrenergic receptor activates adenylyl cyclase, which results in an increase in intracellular cAMP and elicits sequential

downstream signaling that promotes gluconeogenesis and lipolysis in the liver.⁸¹ On the contrary, insulin, through its receptor on the plasma membrane of hepatocytes, activates cyclic nucleotide phosphodiesterases (PDEs) that convert cAMP to AMP and consequently terminates cAMP signaling.⁸² Reciprocally, hydrolysis of cAMP by PDEs in pancreatic β-cells depletes intracellular cAMP levels and inhibits insulin secretion.⁸³

The role of cAMP in the regulation of energy homeostasis has been extended via its intimate relationship with AMP-activated protein kinase (AMPK) signaling. Intracellular cAMP activates the AMPK signaling pathway through its metabolite AMP and by elevating cytosolic Ca₂⁺ concentrations through exchange protein activated by cAMP (Epac1) signaling and, thereby, the activation of calmodulin-dependent protein kinase kinase-β.⁸⁴ AMPK regulates energy balance at both the cellular and whole-body levels.⁸⁵ AMPK inhibits synthesis of both fatty acids and cholesterol by inactivation of acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-coenzyme A reductase.⁸⁵ AMPK opposes gluconeogenesis by inhibiting transcription of critical gluconeogenic enzymes. Activation of AMPK facilitates fatty acid oxidation and mitochondrial biogenesis, which promotes energy expenditure.⁸⁶ Interestingly, activation of AMPK in the hypothalamus promotes food intake behavior.⁸⁷ In some cells, an increase in intracellular cGMP concentration increases cAMP levels by inhibiting PDEs that degrade cAMP.⁸⁸ Indeed, inhibition of PDE4, PDE5, PDE9, and PDE10 decreases the adiposity in mice fed a high-fat diet or in *ob/ob* mice. Recently,



Illustrated by Zina Deretsky

Figure 3 Adenosine 3',5'-cyclic monophosphate (cAMP)- and guanosine 3',5'-cyclic monophosphate (cGMP)-mediated signaling regulates metabolism and energy homeostasis. Increased cGMP levels, via activation of particulate or soluble guanylyl cyclase (pGC or sGC, respectively), activate peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), a master regulator of mitochondrial biogenesis and function. cGMP signaling also regulates the metabolic sensors sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK), which directly activate PGC-1α by deacetylation and phosphorylation, respectively. Resveratrol stimulates mitochondrial function by activating SIRT1 and stimulating cGMP production. Phosphodiesterases (PDEs), which hydrolyze cAMP and cGMP and thereby terminate their signal, are the target for sildenafil, a PDE inhibitor specific for PDE5. Furthermore, cAMP is required for glucose-induced insulin release by pancreatic β-cells. Furthermore, postprandial release of the intestinal hormone uroguanylin results in the endocrine activation of hypothalamic guanylyl cyclase C (GUCY2C) to produce cGMP, which stimulates satiety and suppresses appetite. Moreover, in adipose tissue, cGMP signaling promotes lipolysis and induces adipogenic and thermogenic programs during brown fat cell differentiation through protein kinase G (PKG)-mediated inhibition of RhoA and Rho-associated kinase (ROCK) and, thereby, the activation of phosphoinositide 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog signaling.

emerging evidence suggests that cGMP may regulate energy balance directly.⁸⁹

cGMP is an important second messenger generated by the family of guanylyl cyclases (GCs).⁸⁸ There are two forms of GCs: cytosolic (soluble) and membrane-bound (particulate). Soluble GCs are activated by nitric oxide, whereas particulate GCs are activated upon binding by their cognate ligands, such as the natriuretic peptides (atrial natriuretic peptide and brain natriuretic peptide for GC-A, and C-type natriuretic peptide for GC-B and the intestinal peptides (guanylin and uroguanylin for GC-C (GUCY2C)).⁸⁸ As a critical second messenger, cGMP regulates a variety of physiological processes, and its intracellular concentration is meticulously balanced by the activity of GCs that produce cGMP and PDEs that hydrolyze cGMP.⁸⁸ The role of cGMP in the regulation of energy balance is highlighted by its role in mitochondrial biogenesis⁹⁰ and protection of mitochondrial function from oxidative damage.⁹¹

Mammalian adipose tissue is mainly composed of two types: white adipose tissue (WAT) and brown adipose tissue (BAT).⁹² WAT extracts fat from the circulation and stores the excess energy in the form of triglycerides. WAT is also responsible for the production of hormones, such as leptin, estrogen, and resistin, and inflammatory cytokines.⁹³ BAT is the major tissue that dissipates energy in the form of heat through a process known as nonshivering thermogenesis (Figure 3). BAT generates heat and increases energy expenditure through the mitochondrial transmembrane protein, uncoupling protein 1 (UCP1), which dissipates the energy generated during oxidative phosphorylation in the mitochondria into heat by allowing protons that have been pumped into the intermembrane space to leak back into the mitochondrial matrix.⁹⁴ As a consequence, increasing BAT function or differentiating WAT into BAT may promote energy expenditure and offset the positive energy balance associated with overnutrition to reduce obesity.⁹⁵

In BAT, cGMP signaling has been shown to induce adipogenic and thermogenic programs during brown fat cell differentiation through protein kinase G–mediated inhibition of RhoA and Rho-associated kinase and, thereby, the activation of phosphoinositide 3-kinase–v-akt murine thymoma viral oncogene homolog signaling (Figure 3).⁹⁶ In addition, increasing cGMP levels through cell-permeable cGMP or sildenafil-mediated PDE5 inhibition enhanced BAT differentiation.⁹⁷ Conversely, cGMP signaling, activated by binding of natriuretic peptides (atrial natriuretic peptide and brain natriuretic peptide) to GC-A, triggers lipolytic pathways and mobilizes the fat stored in WAT.⁹⁸ Notably, atrial natriuretic peptide–mediated lipolysis is resistant to hyperinsulinemia and independent of impaired β -adrenergic receptor signaling.⁹⁸ Therefore, “browning” of the WAT via cGMP pathways may be a promising strategy to increase BAT-mediated energy expenditure and decrease WAT-mediated fat storage. Moreover, the ready availability of approved PDE5 inhibitors, such as sildenafil, may significantly facilitate implementing this strategy. In addition to BAT, skeletal muscle is another site for thermogenesis and energy expenditure. Activation of GC-A by natriuretic peptides in skeletal muscle increases cGMP accumulation and promotes energy use through protein kinase G–dependent mitochondrial biogenesis.⁵

GC-C (GUCY2C) is another member of the particulate GC family; its expression has been historically restricted to the intestinal epithelium.⁸⁸ GUCY2C is activated by the endogenous hormones guanylin and uroguanylin in a paracrine fashion in the intestine. GUCY2C signaling defends a variety of homeostatic mechanisms that are crucial to intestinal integrity, including electrolyte and fluid balance, proliferation and differentiation along the intestinal crypt–villus axis, DNA damage sensing and repair, and the barrier function of the intestinal lining.^{99–102} The recent discovery of GUCY2C expression and function in the hypothalamus expands the homeostatic role of GUCY2C. Explicitly, hypothalamic GUCY2C induces satiety responses upon activation by endocrine uroguanylin released from the intestine postprandially.¹⁰³ Furthermore, mice deficient in GUCY2C signaling (*Gucy2c*^{−/−}) have defective satiety responses after food intake, resulting in hyperphagia and excess weight gain.¹⁰³ These mice display obesity-associated disorders, including elevated adiposity, hypertriglyceridemia, hyperleptinemia, hyperinsulinemia, and impaired glycemic control, and develop metabolic diseases, including fulminant diabetes, left-ventricular hypertrophy, and hepatic steatosis.¹⁰³

This gut–brain axis regulating appetite, body weight, and metabolism through GUCY2C signaling¹⁰³ offers a target for the development of pharmacotherapeutic interventions to combat obesity. Targeting GUCY2C signaling would leverage an endogenous endocrine mechanism that sentinels energy homeostasis. Moreover, GUCY2C activation may be achievable with reformulations of existing GUCY2C peptide agonists, such as linaclotide (Linzess, Ironwood Pharmaceuticals, Forest Laboratories) and plecanatide (Synergy Pharmaceuticals). Particularly, linaclotide was approved in 2012 by the FDA and the EMA to treat disorders of gastrointestinal motility (chronic idiopathic constipation, and irritable bowel syndrome with constipation).¹⁰⁴ In clinical trials, patients with chronic constipation improved after 12 or 26 weeks of treatment with 290 μ g oral linaclotide, which had no systemic exposure, was well tolerated, and had minimal adverse effects, diarrhea being the most common.⁵ A phase III trial will be initiated in the fourth quarter of 2013 to evaluate the safety and efficacy of plecanatide for the treatment of chronic idiopathic constipation in patients.

These developments offer new signaling circuits that can be leveraged for weight management. Intriguingly, because both thermogenesis and satiety are increased by activation of these cGMP pathways, stimulating them through drug administration could conceivably drive both of these physiologic processes in the same direction and induce weight loss by mutual reinforcement. Moreover, practical off-the-shelf approaches might be possible, given the existence of an established market for medications targeting cGMP pathways, with FDA- and EMA-approved drugs such as sildenafil and linaclotide.

CONCLUSION

Obesity is a global public health crisis. Obesity-related comorbidities are highlighted by three major causes of death: cardiovascular disease, cancer, and diabetes. In June 2013, the American Medical Association officially recognized obesity

itself as a disease. Obesity profoundly affects morbidity, mortality, health-care costs, and professional and personal quality of life. Awareness of the obesity problem has done little to reverse the obesity trends among the global population. Recent data suggest that growth of the overweight and obese populations in both children and adults have slowed. However, these populations remain substantial and growing. Given that the promotion of lifestyle modifications has proven inadequate, the adjunctive role of medical therapy is vital. The goal is to use drug regimens in combination with improved eating habits and physical activity to achieve a meaningful, sustainable reduction in body weight. However, safety issues throughout the long history of weight-loss drugs had decimated the field, leaving the lipase inhibitor orlistat as the sole drug approved for chronic weight management until 2012, when two new antiobesity drugs were approved by the FDA: lorcaserin and phentermine/topiramate (extended-release formulation). Concerns remain for these new entries, including limited efficacy, carcinogenicity, and cardiovascular risk. Nonetheless, they represent the first new approved chronic weight management drugs in 13 years. Moreover, a host of new antiobesity drugs are in the pipeline, and many epitomize newer strategies in antiobesity drug development designed to minimize risk and maximize efficacy: targeting endogenous endocrine circuits regulating energy homeostasis and metabolism; and combination therapy with monotherapeutic agents to elicit improved safety and efficacy, with potential synergy. These future drugs offer the potential of supplanting or even combining with the newly approved drugs. Finally, the modulation of cGMP signaling in medical weight management has emerged as an intriguing new paradigm for a well-characterized drug class. Discoveries in the molecular mechanisms regulating adipose metabolism and satiety signaling have opened the door for targeting cGMP signaling as a future antiobesity strategy. These advances in the development of antiobesity pharmacotherapy offer new armaments in the fight to reverse the decades-long rise of obesity.

ACKNOWLEDGMENTS

Support was provided by grants from the National Institutes of Health (NIH; P30 CA56036, R01 CA170533), the Pennsylvania Department of Health (SAP 4100059197, SAP 4100051723), and Targeted Diagnostics & Therapeutics. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions. G.W.K. is the recipient of the Graduate Award for Integrative Research in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics and a Predoctoral Fellowship in Pharmacology/Toxicology from the Pharmaceutical Research and Manufacturers of America Foundation. J.E.L. was supported by NIH institutional award T32 GM08562 for Postdoctoral Training in Clinical Pharmacology and is the recipient of the Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics. E.S.B. is the recipient of the Ruth L. Kirschstein National Research Service Award for Individual Predoctoral MD/PhD Fellows (1 F30 CA180500) from the NIH. S.A.W. is the Samuel MV Hamilton Professor of Thomas Jefferson University.

CONFLICT OF INTEREST

S.A.W. is the chair of the Data Safety Monitoring Board for the CHART Trial sponsored by Cardio3 Biosciences and the chair (uncompensated) of the Scientific Advisory Board of Targeted Diagnostics & Therapeutics, which provided research funding that, in part, supported this work; he has a license to commercialize inventions related to this work. S.A.W. is Editor-in-Chief of *Clinical Pharmacology & Therapeutics* but was not involved in the

review or decision process for this article. The other authors declared no conflict of interest.

© 2014 American Society for Clinical Pharmacology and Therapeutics

- Malik, V.S., Willett, W.C. & Hu, F.B. Global obesity: trends, risk factors and policy implications. *Nat. Rev. Endocrinol.* **9**, 13–27 (2013).
- Wang, Y.C., McPherson, K., Marsh, T., Gortmaker, S.L. & Brown, M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet* **378**, 815–825 (2011).
- Kopelman, P.G. Obesity as a medical problem. *Nature* **404**, 635–643 (2000).
- AMA Adopts New Policies on Second Day of Voting at Annual Meeting. <<http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page>> (2013).
- Kim, G.W., Lin, J.E., Blomain, E.S. & Waldman, S.A. New advances in models and strategies for developing anti-obesity drugs. *Expert Opin. Drug Discov.* **8**, 655–671 (2013).
- Obesity Society supports efforts to reduce consumption of sugar-sweetened beverages. <<http://www.obesity.org/news-center/tos-supports-efforts-to-reduce-consumption-of-sugar-sweetened-beverages.htm>> (2012).
- Robert Wood Johnson Foundation. New Report: Adult Obesity Rates Hold Steady But Remain High. <<http://www.rwjf.org/en/about-rwjf/newsroom/newsroom-content/2013/08/new-report--adult-obesity-rates-hold-steady-but-remain-high.html>> (2013).
- DeMaria, E.J. Bariatric surgery for morbid obesity. *N. Engl. J. Med.* **356**, 2176–2183 (2007).
- Zimmet, P. & Alberti, K.G. Surgery or medical therapy for obese patients with type 2 diabetes? *N. Engl. J. Med.* **366**, 1635–1636 (2012).
- Connolly, H.M. *et al.* Valvular heart disease associated with fenfluramine-phentermine. *N. Engl. J. Med.* **337**, 581–588 (1997).
- Asher, W.L. Mortality rate in patients receiving “diet pills.” *Curr. Ther. Res. Clin. Exp.* **14**, 525–539 (1972).
- Kernan, W.N. *et al.* Phenylpropanolamine and the risk of hemorrhagic stroke. *N. Engl. J. Med.* **343**, 1826–1832 (2000).
- Haller, C.A. & Benowitz, N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. *N. Engl. J. Med.* **343**, 1833–1838 (2000).
- US Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). (2010). <<http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm>>
- Topol, E.J. *et al.*; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet* **376**, 517–523 (2010).
- European Medicines Agency. Withdrawal of the marketing authorisation application for Belviq (lorcaserin). (2013). <http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143811.pdf>
- European Medicines Agency. Refusal of the marketing authorisation for Qsiva (phentermine/topiramate). (2013). <http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf>
- Davidson, M.H. *et al.* Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. *JAMA* **281**, 235–242 (1999).
- Public Citizen. Petition to Ban Orlistat (Alli, Xenical). (2011). <<http://www.citizen.org/hrg1942>>
- Song, B.M. & Avery, L. Serotonin activates overall feeding by activating two separate neural pathways in *Caenorhabditis elegans*. *J. Neurosci.* **32**, 1920–1931 (2012).
- Fink, K.B. & Göthert, M. 5-HT receptor regulation of neurotransmitter release. *Pharmacol. Rev.* **59**, 360–417 (2007).
- Yeo, G.S. & Heisler, L.K. Unraveling the brain regulation of appetite: lessons from genetics. *Nat. Neurosci.* **15**, 1343–1349 (2012).
- Heisler, L.K. *et al.* Activation of central melanocortin pathways by fenfluramine. *Science* **297**, 609–611 (2002).
- Heisler, L.K. *et al.* Serotonin reciprocally regulates melanocortin neurons to modulate food intake. *Neuron* **51**, 239–249 (2006).
- Fleming, J.W., McClendon, K.S. & Riche, D.M. New obesity agents: lorcaserin and phentermine/topiramate. *Ann. Pharmacother.* **47**, 1007–1016 (2013).
- Saudou, F. *et al.* Enhanced aggressive behavior in mice lacking 5-HT1B receptor. *Science* **265**, 1875–1878 (1994).
- Xu, Y. *et al.* 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. *Neuron* **60**, 582–589 (2008).
- Wu, Q., Clark, M.S. & Palmiter, R.D. Deciphering a neuronal circuit that mediates appetite. *Nature* **483**, 594–597 (2012).

29. Astrup, A. Drug management of obesity—efficacy versus safety. *N. Engl. J. Med.* **363**, 288–290 (2010).
30. Halford, J.C., Boyland, E.J., Lawton, C.L., Blundell, J.E. & Harrold, J.A. Serotonergic anti-obesity agents: past experience and future prospects. *Drugs* **71**, 2247–2255 (2011).
31. Smith, S.R. *et al.*; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. *N. Engl. J. Med.* **363**, 245–256 (2010).
32. O'Neil, P.M. *et al.* Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. *Obesity (Silver Spring)* **20**, 1426–1436 (2012).
33. Fidler, M.C. *et al.*; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. *J. Clin. Endocrinol. Metab.* **96**, 3067–3077 (2011).
34. Wilding, J., Van Gaal, L., Rissanen, A., Vercruyse, F. & Fitchet, M.; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. *Int. J. Obes. Relat. Metab. Disord.* **28**, 1399–1410 (2004).
35. Astrup, A. *et al.* Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. *Obes. Res.* **12**, 1658–1669 (2004).
36. Bray, G.A. *et al.* A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. *Obes. Res.* **11**, 722–733 (2003).
37. Topamax (Topiramate) [product information]. Titusville, NJ: Janssen Pharmaceuticals, 2012.
38. Richard, D., Ferland, J., Lalonde, J., Samson, P. & Deshaies, Y. Influence of topiramate in the regulation of energy balance. *Nutrition* **16**, 961–966 (2000).
39. Richard, D., Picard, F., Lemieux, C., Lalonde, J., Samson, P. & Deshaies, Y. The effects of topiramate and sex hormones on energy balance of male and female rats. *Int. J. Obes. Relat. Metab. Disord.* **26**, 344–353 (2002).
40. Picard, F., Deshaies, Y., Lalonde, J., Samson, P. & Richard, D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. *Obes. Res.* **8**, 656–663 (2000).
41. Allison, D.B. *et al.* Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). *Obesity (Silver Spring)* **20**, 330–342 (2012).
42. Gadde, K.M. *et al.* Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet* **377**, 1341–1352 (2011).
43. Garvey, W.T. *et al.* Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. *Am. J. Clin. Nutr.* **95**, 297–308 (2012).
44. Vivus. Vivus Announces FDA Approval of Once Daily Qsymia (Phentermine and Topiramate Extended-release) Capsules CIV. <<http://www.vivus.com>>.
45. Hendricks, E.J. *et al.* Addiction potential of phentermine prescribed during long-term treatment of obesity. *Int. J. Obes. (Lond)*. (2013); e-pub ahead of print 17 May 2013.
46. Khazaal, Y. & Zullino, D.F. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. *Eur. J. Clin. Pharmacol.* **63**, 891–2; author reply 893 (2007).
47. McElroy, S.L., Hudson, J.I., Capece, J.A., Beyers, K., Fisher, A.C. & Rosenthal, N.R.; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. *Biol. Psychiatry* **61**, 1039–1048 (2007).
48. Shin, J.H. & Gadde, K.M. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. *Diabetes. Metab. Syndr. Obes.* **6**, 131–139 (2013).
49. Krishna, R. *et al.* Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. *Clin. Pharmacol. Ther.* **86**, 659–666 (2009).
50. Wikberg, J.E. & Mutulis, F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. *Nat. Rev. Drug Discov.* **7**, 307–323 (2008).
51. Wessells, H., Gralnek, D., Dorr, R., Hruby, V.J., Hadley, M.E. & Levine, N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. *Urology* **56**, 641–646 (2000).
52. Larhammar, D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. *Regul. Pept.* **65**, 165–174 (1996).
53. Omori, N. *et al.* Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. *Bioorg. Med. Chem. Lett.* **22**, 2020–2023 (2012).
54. Eröndü, N. *et al.* Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. *Cell Metab.* **4**, 275–282 (2006).
55. Sargent, B.J. & Moore, N.A. New central targets for the treatment of obesity. *Br. J. Clin. Pharmacol.* **68**, 852–860 (2009).
56. Greenway, F.L. *et al.* Rational design of a combination medication for the treatment of obesity. *Obesity (Silver Spring)* **17**, 30–39 (2009).
57. Pittner, R.A. *et al.* Molecular physiology of amylin. *J. Cell. Biochem.* **55** (suppl.), 19–28 (1994).
58. Koda, J.E., Fineman, M., Rink, T.J., Dailey, G.E., Muchmore, D.B. & Linarelli, L.G. Amylin concentrations and glucose control. *Lancet* **339**, 1179–1180 (1992).
59. Edwards, G.L., Gedulin, B.R., Jodka, C., Dilts, R.P., Miller, C.C. & Young, A. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin. *Neuro. Gastroenterol. Motil.* **10**, 26 (1998).
60. Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T. & Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. *Int. J. Obes. Relat. Metab. Disord.* **25**, 1005–1011 (2001).
61. Maggs, D., Shen, L., Strobel, S., Brown, D., Kolterman, O. & Weyer, C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. *Metab. Clin. Exp.* **52**, 1638–1642 (2003).
62. Montague, C.T. *et al.* Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* **387**, 903–908 (1997).
63. Farooqi, I.S. & O'Rahilly, S. Monogenic obesity in humans. *Annu. Rev. Med.* **56**, 443–458 (2005).
64. Ozcan, L. *et al.* Endoplasmic reticulum stress plays a central role in development of leptin resistance. *Cell Metab.* **9**, 35–51 (2009).
65. Roth, J.D. *et al.* Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. *Proc. Natl. Acad. Sci. USA* **105**, 7257–7262 (2008).
66. Ravussin, E. *et al.* Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. *Obesity (Silver Spring)* **17**, 1736–1743 (2009).
67. Amylin Pharmaceuticals. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial. (2011). <http://www.takeda.com/news/2011/20110317_3836.html>
68. Müller, T.D. *et al.* Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. *J. Pept. Sci.* **18**, 383–393 (2012).
69. Drucker, D.J. The biology of incretin hormones. *Cell Metab.* **3**, 153–165 (2006).
70. Meeran, K. *et al.* Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. *Endocrinology* **140**, 244–250 (1999).
71. Turton, M.D. *et al.* A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* **379**, 69–72 (1996).
72. Flint, A., Raben, A., Astrup, A. & Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. *J. Clin. Invest.* **101**, 515–520 (1998).
73. Näslund, E. *et al.* Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. *Br. J. Nutr.* **91**, 439–446 (2004).
74. Michel, M.C., Fliers, E. & Van Noorden, C.J. Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? *Naunyn Schmiedeberg's Arch. Pharmacol.* **377**, 205–207 (2008).
75. Amori, R.E., Lau, J. & Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *JAMA* **298**, 194–206 (2007).
76. Fakhoury, W.K., Lereun, C. & Wright, D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. *Pharmacology* **86**, 44–57 (2010).
77. Phung, O.J., Scholle, J.M., Talwar, M. & Coleman, C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. *JAMA* **303**, 1410–1418 (2010).
78. Pratley, R.E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. *Medscape J. Med.* **10**, 171 (2008).
79. Batterham, R.L. *et al.* Inhibition of food intake in obese subjects by peptide YY3-36. *N. Engl. J. Med.* **349**, 941–948 (2003).
80. Sutherland, E.W. & Robison, G.A. The role of cyclic AMP in the control of carbohydrate metabolism. *Diabetes* **18**, 797–819 (1969).
81. Unger, R.H., Dobbs, R.E. & Orci, L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. *Annu. Rev. Physiol.* **40**, 307–343 (1978).

82. Marchmont, R.J. & Houslay, M.D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. *Biochem. J.* **187**, 381–392 (1980).
83. Zhao, A.Z., Zhao, H., Teague, J., Fujimoto, W. & Beavo, J.A. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. *Proc. Natl. Acad. Sci. USA* **94**, 3223–3228 (1997).
84. Hawley, S.A. *et al.* Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metab.* **2**, 9–19 (2005).
85. Hardie, D.G. & Frenguelli, B.G. A neural protection racket: AMPK and the GABA(B) receptor. *Neuron* **53**, 159–162 (2007).
86. Narkar, V.A. *et al.* AMPK and PPARdelta agonists are exercise mimetics. *Cell* **134**, 405–415 (2008).
87. Minokoshi, Y. *et al.* AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* **428**, 569–574 (2004).
88. Lucas, K.A. *et al.* Guanylyl cyclases and signaling by cyclic GMP. *Pharmacol. Rev.* **52**, 375–414 (2000).
89. Degerman, E. *et al.* From PDE3B to the regulation of energy homeostasis. *Curr. Opin. Pharmacol.* **11**, 676–682 (2011).
90. Nisoli, E. *et al.* Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. *Science* **299**, 896–899 (2003).
91. Jang, Y., Wang, H., Xi, J., Mueller, R.A., Norfleet, E.A. & Xu, Z. NO mobilizes intracellular Zn²⁺ via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes. *Cardiovasc. Res.* **75**, 426–433 (2007).
92. Cypess, A.M. *et al.* Identification and importance of brown adipose tissue in adult humans. *N. Engl. J. Med.* **360**, 1509–1517 (2009).
93. Trujillo, M.E. & Scherer, P.E. Adipose tissue-derived factors: impact on health and disease. *Endocr. Rev.* **27**, 762–778 (2006).
94. Parker, N., Crichton, P.G., Vidal-Puig, A.J. & Brand, M.D. Uncoupling protein-1 (UCP1) contributes to the basal proton conductance of brown adipose tissue mitochondria. *J. Bioenerg. Biomembr.* **41**, 335–342 (2009).
95. Kozak, L.P. & Koza, R.A. The genetics of brown adipose tissue. *Prog. Mol. Biol. Transl. Sci.* **94**, 75–123 (2010).
96. Haas, B. *et al.* Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. *Sci. Signal.* **2**, ra78 (2009).
97. Mitschke, M.M. *et al.* Increased cGMP promotes healthy expansion and browning of white adipose tissue. *FASEB J.* **27**, 1621–1630 (2013).
98. Moro, C., Galitzky, J., Sengenès, C., Crampes, F., Lafontan, M. & Berlan, M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. *J. Pharmacol. Exp. Ther.* **308**, 984–992 (2004).
99. Li, P., Lin, J.E., Chervoneva, I., Schulz, S., Waldman, S.A. & Pitari, G.M. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. *Am. J. Pathol.* **171**, 1847–1858 (2007).
100. Li, P. *et al.* Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. *Gastroenterology* **133**, 599–607 (2007).
101. Lin, J.E. *et al.* The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. *Gastroenterology* **138**, 241–254 (2010).
102. Lin, J.E. *et al.* GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. *PLoS ONE* **7**, e31686 (2012).
103. Valentino, M.A. *et al.* A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. *J. Clin. Invest.* **121**, 3578–3588 (2011).
104. Ray, K. IBS: Linaclotide approved for constipation-predominant IBS. *Nat. Rev. Gastroenterol. Hepatol.* **9**, 616 (2012).